Platelet functions and clinical effects in acute myelogenous leukemia

Brynjar Foss1, Øystein Bruserud2
1Department of Health Studies, University of Stavanger, Norway; 2Institute of Medicine, Haukeland University Hospital, University of Bergen, Norway

Summary
Platelets interact with normal peripheral blood cells via adhesion as well as soluble mediators, and platelet released mediators can affect hematopoietic stem and progenitor cells. Interactions may also be involved between platelets and circulating malignant cells, which is suggested by the effects platelets seem to have on metastasis and the various platelet abnormalities observed in various malignant disorders, including acute myelogenous leukemia (AML) and other leukemias. It is only recently that the interactions between platelets and AML cells have been characterized in detail, and studies show that; i) platelets and AML blasts can affect functional characteristic of each other, ii) chemotherapeutic drugs frequently used in AML therapy can alter several platelet functions, iii) the systemic levels of various cytokines are enhanced during AML chemotherapy, including cytokines known to affect both leukemic blasts and platelet activation, and iv) platelet secretion of growth factors are clearly detected in peripheral blood stem cells autografts. In this review we describe platelet interactions with normal leukocytes, normal hematopoietic and leukemic cells and the possible clinical relevance of these interactions in AML.

Keywords
Platelets, hematopoiesis, AML, chemotherapy, PBSCT

Introduction
Platelets normally play a role in hemostasis (1) and are involved in the activation of immunocompetent cells (2). Thus, platelets interact with normal blood cells during physiological processes. Similarly, platelets can also interact with malignant cells including leukemic blasts (3, 4) and have been indicated to play a significant role in tumour metastasis (5). However, it has not yet been characterized in detail whether platelet interactions are important for carcinogenesis or treatment responsiveness of malignancies. Previous studies suggest that platelets interact with acute myelogenous leukemia (AML) blasts both in vitro and in vivo (3, 4, 6–8), and may be important during conventional chemotherapy as well as peripheral blood stem cells transplantation (PBSCT) (9–11). Here we describe platelet interactions with normal leukocytes, normal hematopoietic and leukemic cells and discuss the possible clinical relevance of these interactions in AML.

Platelets
Platelets store several biologically active molecules, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), platelet factor-4 (PF-4) (Table 1) and Angiopoietin-1 (Ang-1) (12). During in-vivo vessel wall rupture and bleeding platelets become adherenta and activated. Platelet activation is among other things characterized by secretion of the biologically active molecules from α-granula and dense bodies (Table 1) (1, 2). Activated platelets also release smaller membrane vesicles, the platelet-derived microparticles (PDMP) (2), which at least express tissue factor (TF) and seem to be involved in the regulation of thrombus formation (13). The activated platelets increased stickiness is due to expression of activation dependent adhesion molecules including GPIIb/IIIa (CD41/CD61, fibrinogen receptor) and CD62P (1, 2). These molecules induce platelet aggregation and adhesion with subendothelium, endothelial cells and leukocytes (1, 2) and thereby participate in the mechanism of bleeding arrest.
Thrombin, collagen, adenosine diphosphate (ADP), thromboxane A$_2$ (TXA$_2$) and von Willebrand factor are all physiological platelet activators (1, 2). In addition to physiological mediators, various forms of stress, including centrifugation and exposure to artificial surfaces, can also induce platelet activation. This is observed during clinical procedures that involve extracorporeal circulation including collection of peripheral blood hematopoietic stem cells (10, 11, 14, 15).

The role of platelets in specific variants of AML

Later on in this review we will go on to discuss the possible importance of platelets in AML in general. However, two specific variants of AML clearly differ from other subsets, namely the acute promyelocytic variant and the acute megakaryoblastic leukemia, and the role of platelets may thus be different for these two subsets.

Acute promyelocytic leukemia (APL)

The acute promyelocytic variant of AML is characterized by specific genetic abnormalities, predominant signs of promyelocytic differentiation in the leukemic cells and a dramatic clinical presentation different from other AML patients (16). A high proportion of patients with APL has coagulation problems. As described in detail in a recent review (16), the pattern of coagulation abnormalities in most patients at presentation is consistent with intravascular coagulation activation, and thrombocytopenia is a part of this. The molecular mechanisms behind the activation are not known in detail, but TF is expressed by the promyelocytic blasts, and the cancer procoagulant cytistein protease is also expressed at higher levels in APL cells than by other AML cell subsets (16, 17). All these observations suggest that the role of platelets in APL differ from the other subtypes, and the guidelines for platelet transfusions also differ. The British Society for Haematology Guidelines state that platelet counts should be kept above $20 \times 10^9$/l also in the absence of fever or bleedings, and other authors have suggested that maintaining platelet counts above $50 \times 10^9$/l during the first 10 days of treatment, especially in those who are actively bleeding, will reduce the risk of early haemorrhagic death (16).

Acute megakaryoblastic leukemia (AML-M7)

AML-M7 occurs in two age groups, young children and adults. AML-M7 seems to be a heterogeneous group: Down syndrome associated, t(1;22) associated and those with other abnormalities (18). The two first are childhood disorders. The disease is often characterized by organomegaly, thrombocytosis may be seen, the bone marrow often shows fibrosis and associated myelodysplastic changes, and as explained above for many patients leukemogenesis depends on specific genetic abnormalities (i.e. trisomy8, t(1;21), mutations of the GATA1 transcription factor) (18, 19). As would then be expected, gene expression profiles are also different for AML-M7 compared with other subsets, class-discriminating genes have been identified but in addition there seems to be a heterogeneity with different subsets within the M7 group (20, 21). Taken together, these observations suggest that AML-M7 is a specific entity, functional characteristics of these leukemic cells probably differ from other AML subtypes and the role of platelets in this variant is possibly also different.

Platelet interactions with normal and malignant cells

Platelet interactions with normal leukocytes

Several studies have shown that normal platelets and leukocytes adhere well to each other and interfere functionally (2) (Table 2). Here we review some of these interactions. Thrombin activated

---

**Table 1: Platelet granula contents.**

<table>
<thead>
<tr>
<th>Granula</th>
<th>Substance group</th>
<th>Molecule</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-granula</td>
<td>Growth factors</td>
<td>Platelet-derived growth factor (PDGF)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transforming growth factor-β (TGF-β)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Epidermal growth factor (EGF)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vascular endothelial growth factor (VEGF)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thrombopoietin (TPO)</td>
</tr>
<tr>
<td></td>
<td>Platelet specific proteins</td>
<td>β-thromboglobulin (β-TG)</td>
</tr>
<tr>
<td></td>
<td>Coagulation factors</td>
<td>Factor V, VII, XI, XIII</td>
</tr>
<tr>
<td></td>
<td>Glycoprotein</td>
<td>Thrombospondin (TSP)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fibronectin</td>
</tr>
<tr>
<td></td>
<td>Dense bodies</td>
<td>Serotonin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ATP, ADP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ca$^{2+}$</td>
</tr>
</tbody>
</table>

**Table 2: Adhesion molecules involved in platelet adhesion to normal leukocytes and bone marrow cells.**

<table>
<thead>
<tr>
<th>Platelet adhesion molecule</th>
<th>Ligand-expressing cells</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD62P</td>
<td>Monocytes</td>
<td>23, 25</td>
</tr>
<tr>
<td></td>
<td>Neutrophils</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Eosinophils</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Basophils</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Polymorphonuclear leukocytes (PMN)</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>T-cell subpopulations</td>
<td>25, 26</td>
</tr>
<tr>
<td>CD41a / fibrinogen</td>
<td>Polymorphonuclear leukocytes</td>
<td>27</td>
</tr>
<tr>
<td>Thrombospondin (TSP)</td>
<td>Bone marrow cells</td>
<td>28</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>Bone marrow cells</td>
<td>29</td>
</tr>
</tbody>
</table>

vWF, von Willebrand factor; ATP, adenosine triphosphate; ADP, adenosine diphosphate. Table is based on (1, 2, 164).
Platelets adhere well to monocytes and polymorphonuclear leukocytes (PMN) (22), and platelet adhesion to monocytes seems to be favoured over neutrophils (23) and is mediated via the CD62P membrane molecule (24). Adhesion is also observed for eosinophils, basophils and subpopulations of T-lymphocytes (25, 26). However, other membrane molecules may also be involved, including CD41a and fibrinogen (27). In addition, both thrombospondin-1 (TSP) and fibronectin bind bone marrow cells (28, 29) and may therefore be involved in normal platelet-leukocyte adhesion.

Leukocytes can affect platelet aggregation, induce intraplatelet Ca$^{2+}$ fluctuations and increase platelet thromboxane B$_2$ production by adhesion or via released mediators (30). In addition, leukocyte released interleukin (IL)-1 and interferon-γ induce platelet expression of CD62P that enhance platelet-leukocyte adhesion (31). Platelets, on the other hand, can release NAP-2 that enhance platelet-leukocyte adhesion (31). Platelets, on the other hand, can release NAP-2 that enhance platelet-leukocyte adhesion (31). Platelets, on the other hand, can release NAP-2 that enhance platelet-leukocyte adhesion (31). Platelets, on the other hand, can release NAP-2 that enhance platelet-leukocyte adhesion (31). Platelets, on the other hand, can release NAP-2 that enhance platelet-leukocyte adhesion (31). Platelets, on the other hand, can release NAP-2 that enhance platelet-leukocyte adhesion (31).

Platelet effects on normal hematopoietic cells
Platelets can also bind (38), and via released mediators, affect hematopoietic stem cells (Table 3). PDGF can alter proliferation of hematopoietic progenitors (39), including enhance expansion of CD34$^+$ cells (40). However, PDGF may not have direct effects on CD34$^+$ cells because this progenitor subset seems to lack its receptor (41) or develops it later in culture (40). TGF-β (Transform growth factor β) divergently affects hematopoietic stem cells (42), but is stored in platelets as a poorly active complex (43). TSP and Fibronectin adhere to bone marrow cells (28, 29) and can alter megakaryocytepoiesis and hematopoietic stem cells, respectively (44, 45). Fibrinogen can also affect the growth of bone marrow cells (46). VEGF possibly regulates hematopoietic stem cell survival (47) and can affect hematopoietic cells by suppressing apoptosis (48) and divergently alter colony growth (49). PF-4, β-thromboglobulin (β-TG) and Serotonin can all affect megakaryocyte cell growth (50–52), and PF-4 in addition supports the survival of myeloid progenitors (53) and promotes the adhesion of hematopoietic stem cells (54). The fact that CD34$^+$ cells themselves produce and respond to VEGF and PF-4, amongst several other growth factors, indicates that these factors do play a physiological role in normal hematopoiesis (55). Furthermore, PDMP’s seem to alter several functions of hematopoietic cells, including survival, proliferation and adhesion (56).

To conclude so far, platelets can interact both with mature myeloid cells and immature hematopoietic stem or progenitor cells through several molecular mechanisms. The clinical importance of these interactions in AML is not yet known. Patients with AML may have increased levels of circulating activated platelets and possible effects of local platelet activation are: i) altered function of immunocompetent cells in these severely immunocompromised patients, or ii) modulation of remaining normal hematopoiesis in the bone marrow compartment that is slowed by the dominating AML cell population and a minor cell subset of normal hematopoietic cells (for further discussion, continue).

<table>
<thead>
<tr>
<th>Platelet released mediator</th>
<th>Hematopoietic cell type</th>
<th>Effect</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet-derived growth factor (PDGF)</td>
<td>Progenitors</td>
<td>Cell growth</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>CD34$^+$ cells</td>
<td>Expansion</td>
<td>40</td>
</tr>
<tr>
<td>Transforming growth factor-β (TGF-β)</td>
<td>Stem cells</td>
<td>Cell growth (differently affects)</td>
<td>42</td>
</tr>
<tr>
<td>Thrombospondin (TSP)</td>
<td>Megakaryocytic cells</td>
<td>Inhibiting colony formation</td>
<td>44</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>Stem cells</td>
<td>Increase CFU-GEMM</td>
<td>45</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>Bone marrow CD34$^+$ cells</td>
<td>Increase BFU-E</td>
<td>46</td>
</tr>
<tr>
<td>Vascular endothelial growth factor (VEGF)</td>
<td>Stem cells</td>
<td>Apoptosis</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Colony growth</td>
<td>49</td>
</tr>
<tr>
<td>Platelet factor-4 (PF-4)</td>
<td>Megakaryocytic cells</td>
<td>Cell growth</td>
<td>50, 51</td>
</tr>
<tr>
<td></td>
<td>Myeloid progenitors</td>
<td>Survival</td>
<td>53</td>
</tr>
<tr>
<td>β-thromboglobulin (β-TG)</td>
<td>Megakaryocytic cells</td>
<td>Cell growth</td>
<td>51</td>
</tr>
<tr>
<td>Serotonin</td>
<td>Megakaryocytic cells</td>
<td>Cell growth</td>
<td>52</td>
</tr>
</tbody>
</table>

Table 3: Effects of different platelet-released mediators on hematopoietic cells.
Platelet interactions with neoplastic hematopoietic cells

There is clear evidence that platelets are altered in several malignancies and interfere with malignant cells. At least three types of platelet-malignancy interactions occur: i) altered platelet activation (57–59); ii) platelet effects on malignant cell growth (60), and iii) platelet enhancement of metastasis (5). Here we briefly describe some of these interactions.

Abnormally high levels of the platelet specific proteins β-TG and PF-4 are detected in patients with active or progressive malignant disease (61), and elevated in-vivo levels of PDMP are described for gastric cancer (57) and myeloproliferative syndromes (58). Platelet activation is further observed during tumour development (59). This indicates that there might be an ongoing platelet activation in patients with malignant diseases. In addition, malignant cells can induce platelet aggregation and activate platelets by ADP secretion (62). On the contrary, decreased and abnormal platelet aggregation is described for chronic myeloproliferative disorders and acute lymphoblastic leukemia (63, 64). However, it is uncertain whether this is directly caused by the malignant cells.

Platelets can affect tumour cells via their release of soluble mediators (65). VEGF is stored in and released by activated platelets (2) and may affect tumour growth via direct effects on malignant cells, or indirectly via its effects on angiogenesis (66–68). PDGF, also released by platelets (1), can affect malignant cells. PDGF receptors are expressed by several tumours and are related to both tumour growth directly and indirectly via angiogenesis (60). Such receptors are among others described on chronic lymphocytic leukemia cells (69). The widespread expression of PDGF receptors in tumours makes it a possible target for cancer drugs (70) which suggests that PDGF plays an important role in malignancies and that platelets might affect these functions. Other platelet-released mediators that can affect malignant cells are: i) TGF-β that can affect leukemic HL-60 myeloid cells (71); ii) PF-4 that may affect tumour invasion (72), and interestingly iii) TSP and fibronectin that are suggested to be involved in cancer metastasis (73, 74).

The aforementioned observations clearly illustrate the wide range of molecular mechanisms that can be involved in the interactions between circulating platelets and malignant cells.

Clinical importance of platelets in AML

AML is characterised by malignant myeloid cells that show neoplastic proliferation with a differentiation block. This results in the accumulation of immature blasts in the bone marrow that frequently leads to hematopoietic insufficiency with peripheral blood cytopenia as well as functional alterations of the remaining cells.

Platelet abnormalities in AML

It has been known since the early 70’s that platelets may show a wide range of defects in acute leukemias, including abnormal metabolism, lifespan and aggregation (see [75, 76] and references therein). Several groups have verified these results and characterized additional platelets dysfunctions in AML. These include abnormal platelet aggregation (77–81), abnormal platelet factor-3 (PF-3) activity (78), dysfunction in the release reaction and thromboxane B2 production (79), abnormal plasma PF-4 and serotonin levels (80, 82), abnormal platelet volumes (83), dense granula abnormalities (83, 84), abnormal clot retraction and prolonged bleeding time (77). Hemorrhage and thrombosis are well known in acute promyelocytic leukemia (85, 86). In addition, platelet abnormalities/activation have also been detected for chronic myelogenous and lymphocytic leukemia (58, 87) suggesting that platelet abnormalities might be of a more general phenomenon in leukemias. However, these abnormalities may be of particular importance in AML where they usually occur in combination with a rapidly progressive malignancy with a severe quantitative platelet defect.

Platelet – AML blast interactions in vitro

Native myeloid leukemic cells and cells from the AML cell line HL-60 can alter platelet function by inhibiting aggregation (88). In addition, native AML blasts seem to increase the platelet PDGF and soluble CD62P secretion in vitro (4). Thus, leukemic blasts are suggested to alter platelet activation in vitro. On the other hand, normal platelets can alter AML blast proliferation and constitutive cytokine secretion in vitro (3). This is caused both via direct adhesion (3) and via platelet release of soluble mediators, including PDGF, PF-4 and VEGF (3, 6, 7). These observations are further supported by studies showing that these mediators affect the function of other malignant and normal hematopoietic cells: PDGF that is released by platelets in co-culture with AML blast (4) is a growth factor for normal hematopoietic and chronic myelogenous leukemia cells (39, 89). PF-4 regulates apoptosis and supports the survival of normal myeloid cells (53), including megakaryocyteopoeisis (50, 51). It is also elevated in peripheral blood of AML patients (80, 82). AML cells can express VEGF receptors (90) and VEGF can affect both normal and leukemic hematopoiesis (47–49, 91). The clinical importance of VEGF is also shown by its prognostic impact in AML patients receiving intensive chemotherapy (92–94).

Possible effects of complex cytokine networks in vivo

The clinical importance of platelets and platelet released mediators in AML is not well characterized. Previous observations have shown that both acute and chronic lymphoid and myeloid leukemia cells can release PAF in the active phase of the disease (95), thus possibly affecting platelet activation in vivo. Other in-vitro studies suggest that platelet interactions with AML blasts may be important in clinical settings. Via adhesion and/or activation platelets may create or modulate local as well as systemic cytokine networks that affect AML blast functions. We previously showed that the cytokines thrombopoietin (TPO), G-CSF and Flt3-L are elevated in AML patients with chemotherapy induced cytopenia (96). The increased levels of TPO and the high levels of SCF in AML (96) may affect platelet activation in AML patients (97–99) and thereby the secretion of various growth factors capable of altering AML blasts. In addition, TPO and IL-6 can increase the number of released PDMP (100), which can alter normal hematopoietic cell functions (56) and possibly also leukemic cells characteristics. Furthermore, various studies showed increased systemic levels of cytokines in AML, including intercellular adhesion molecule-1 (ICAM-1) (101,
102), IL-6 (101–104), IL-2, TNF-α (105), EPO (106), IL-8 (103), G-CSF (103, 104) and IL-10 (104). Thus, growth factors released by activated platelets together with disease- and chemotherapy-induced modulation of local and systemic cytokine levels create a unique cytokine network in AML patients. This network may then affect disease development as well as chemosensitivity in human AML.

**Effects of chemotherapeutic drugs on platelet functions**

Patients with malignant diseases can develop quantitative platelet defects due to chemotherapy-induced bone marrow toxicity. Cytotoxic drugs may also induce qualitative platelet defects with abnormalities both in platelet secretion and aggregation (107) (Table 4). Studies performed in the beginning of the 70’s showed that various cytotoxic drugs, including cytarabine and doxorubicin, could alter platelet functions (108, 109). The anticyclic doxorubicin can also inhibit platelet aggregation (110), platelet release reaction and affect protein phosphorylation (111). Platelet aggregation is also inhibited by vincristine and epirubicin (110), whereas daunorubicin can induce platelet and mitochondrial swelling, vacuole formation, decreased aggregation, decreased serotonin release, inhibition of platelet prostaglandin pathway and decreased availability of PF-3, and for high concentrations even platelet lysis has been observed (111–113).

We previously studied the effects of cytotoxic drugs and various anticyclics on normal whole blood platelet activation using flow cytometry. Both daunorubicin and higher doses of idarubicin enhance platelet expression of GPIIb/IIIa, CD62P and CD63, indicating that platelets were highly activated (8). Both these anticyclics were also absorbed by the platelets. Although the liposomal form of daunorubicin was absorbed by platelets as well, it did not enhance platelet activation in our study. Thus, several cytotoxic agents commonly used in AML therapy seem to affect various platelet functions.

**Platelet activation and adhesion in AML patients in vivo**

Although high systemic levels of the platelet-activating cytokine TPO is detected (96) and chemotherapeutic drugs relevant for AML can affect platelet functions, a general activation pattern of circulating platelets derived from AML patients during chemotherapy was not detected in our previous study (8). These findings are later confirmed where the expression of platelet activation markers actually was decreased compared to healthy volunteers (81). However, elevated CD63 expression, which is usually expressed on highly activated platelets (114, 115), was detected for a subset of our AML patients prior to chemotherapy, an expression heterogeneity of platelet activation markers that is later confirmed (81). The absence or low levels of fibrinogen receptor and CD62P expression suggest that this CD63 expression should be regarded as a single platelet dysfunction in AML and possibly not as a sign of true platelet activation, just like the low expression of fibrinogen receptor and CD62P (81). But these results may also be explained by reversal of fibrinogen receptor expression (116) and CD62P release (117) after activation (8). It is worth noting that our observations seem to be in contrast to previous reports describing drug-induced modulation of platelet activation in AML (107–113, 118). However, these studies and the previous studies that describe platelet dysfunctions in AML (77–80) are mainly in-vitro investigations, whereas our study address the in-vivo status of the platelets. Another possible explanation for the conflicting observations could be that activated platelets adhere to AML blasts in our patients with high levels of circulating blasts (8). Thus, platelet abnormalities can be detected in AML, but these abnormalities do not represent a conventional activation pattern with development of the normal activated platelet phenotype.

**Clinical importance of platelets in stem cell transplantation**

Another important setting where platelets may play a significant role is during stem cell transplantation. In a previous study, both PDMP and platelets released mediators, including TPO, increased after auto- and allo-transplantation (119) possibly indicating platelet activation in vivo. Furthermore, both platelets and leukocytes become activated during the collection of mobilized stem cells (14, 120, 121) partly detected by elevated levels of P-selectin, TPO and PDMP (11). In addition, platelets and leukocytes are increased in PBSC autografts (9, 10, 15, 122, 123). Malignant cells may also contaminate autografts, and AML blast contamination may occur in PBSC grafts even when it cannot be detected in the bone marrow collection (124–127). Importantly, graft contaminating malignant cells may be responsible for post-transplant relapse (128–130). We have previously described that the platelet released mediators PF-4, β-TG and PDGF-AB are increased in the autografts compared with peripheral blood, which demonstrates that platelets are activated and make a detectable contribution to a unique cytokine network in autografts (9, 10). In addition, high levels of the hematopoietic growth factors TPO, EPO, IL-6, IL-2, TNF-α, and G-CSF, as well as IL-8, and IL-10, create a unique cytokine network in AML patients. This network may then affect disease development as well as chemosensitivity in human AML.

### Table 4: Effects of chemotherapeutic drugs on platelet functions.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Effect</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daunorubicin</td>
<td>Platelet swelling</td>
<td>113</td>
</tr>
<tr>
<td></td>
<td>Vacuole formation</td>
<td>113</td>
</tr>
<tr>
<td></td>
<td>Decreased aggregation</td>
<td>112,113</td>
</tr>
<tr>
<td></td>
<td>Decreased serotonin release</td>
<td>111</td>
</tr>
<tr>
<td></td>
<td>Platelet lysis (high concentrations)</td>
<td>113</td>
</tr>
<tr>
<td></td>
<td>Increased expression of CD62P *8</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Increased expression of CD63 #8</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Increased expression of GPIIb/IIIa #8</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Increased expression of GPIIb/IIIa #8</td>
<td>8</td>
</tr>
</tbody>
</table>

* # = in-vivo studies.
GM-CSF and Flt3-L were also detected in autografts (10, 131), whereas GM-CSF and Flt3-L levels were increased in peripheral blood (131). Thus, both the peripheral blood and the autografts of these patients seem to contain unique cytokine networks, and platelet released mediators contribute to the cytokine network in the autografts. These observations were made in patients with different malignancies, but similar results were detected for all patients independent of their primary disease (10). Thus, platelet activation is most likely dependent on the apheresis procedure (14, 132, 133), and the results are therefore also relevant for patients with other malignant disorders. It is important to note that different apheresis procedures might yield different amounts of platelets and possibly different levels of platelet released mediators (133). Still, taken together with the in-vitro results (3, 6, 7) our and others observations suggest that normal hematopoietic stem cells and contaminating AML blasts in PBSCT autografts are exposed to a local cytokine network, including platelet released growth factors that may alter their functional characteristics. It is not yet known whether these effects are clinically relevant, but as discussed by Bruserud et al. (9) this may be a mechanism for graft platelets to affect the risk of post-transplant relapse.

**Platelet transfusions and bleeding complications in AML**

AML patients are at increased risk of bleeding due to the disease-related lack of platelets, platelets dysfunctions and systemic coagulopathy. Platelet transfusion may therefore be life saving therapy to achieve hemostasis in the bleeding patients. The transfusions are traditionally given at a platelet threshold of 20,000/μl, however, lower thresholds have since been established for stable patients who do not have a fever or active hemorrhage (134). Interestingly, due to different methods used in the production of platelet concentrates (135), refactoriness to platelet transfusion due to alloimmunisation (135) and altered functions by stored platelets (136), it may be difficult to predict the effect of platelet transfusions on AML blast functions. To the best of our knowledge, no studies have examined the possible effects of transfused platelets on leukemic cells, and the possibility can not be excluded that transfused platelets will affect AML cell functions, including chemosensitivity.

Thrombosis is not negligible in hematologic malignancies (137, 138), and several thrombogenic factors are present in AML patients. Firstly, platelet activation can be present (see before). Secondly, TF seem to be involved in venous thromboembolism (138), whereas TF-positive PDMP seem to be involved in hemostasis activation in cancer patients (139). Thirdly, circulating CD62P (P-selectin) may also be a risk factor for venous thromboembolism (140). This molecule is released by platelets co-cultured with AML blasts in vitro (4) and may also be released in vivo by activated platelets (8, 117). Finally, an in-vitro study showed that TF induced procoagulant activity can be affected by cytotoxic drugs used in AML therapy (141). Thus, several mechanisms may contribute to procoagulant activity in AML and TF, which also seems to be involved in the mechanisms of disseminated intravascular coagulation in promyelocytic leukemia (16), might be one of the most important mechanisms (16). Platelets may then contribute via their PDMP (139).

Despite increased procoagulant activity, the major problem in AML patients is severe haemorrhages and not thromboembolic complications (16), even though the AML cells express TF as well as other factors that can activate coagulation (16, 17). The most likely explanation for this discrepancy is that the severe disease- and therapy-induced thrombocytopenia in these patients counteract the procoagulant activity. The most common thrombotic manifestation seems to be central-line associated thrombosis that has been reported to occur in up to 40–50% of patients when using sensitive Doppler-ultrasound of the catheterized vein for visualization, but usually the thromboses are asymptomatic and may even resolve spontaneously (142).

**Circulating reticulated platelets as a marker of hematopoietic reconstitution after intensive chemotherapy**

Reticulated platelets can be detected in the circulation at low levels during the period of severe treatment-induced thrombocytopenia following intensive chemotherapy, and this is also true in AML (143, 144). However, prior to hematopoietic reconstitution with increasing peripheral blood platelet counts an increase in the absolute count and percentage of reticulated platelets can be detected (143, 144), and results from initial clinical studies suggest that the requirement for prophylactic platelet transfusion can be reduced according to the patients’ reticulated platelet increase. The study by Chaoui et al. (144) included patients with various hematologic malignancies treated with autologous stem cell transplantation, and it is unknown whether these observations are relevant for AML patients receiving repeated cycles with conventional intensive chemotherapy.

**The role of platelets in AML-M7 and myelofibrosis**

Due to the fact that platelets are produced from the megakaryocytes in the bone marrow and that megakaryocytes store biological active mediators as platelets, it is possible that platelets and/or platelet stored mediators may be involved in the AML-M7 and other AML-M7 associated diseases. Whereas AML-M7 is not very common, myelofibrosis, which is associated to most kinds of AML but mostly to de novo AML-M7, is relatively more frequent. Unfortunately, interactions of platelets and cells involved in AML-M7 and myelofibrosis are not well characterized. However, we will present here some possible effects that platelet released mediators may be involved in.

In AML-M7 and other subtypes of AML with the cytogenetic abnormality involving 3q21, increased platelet number and presence of micromegakaryocytes are common (145, 146). Marked polymorphism of blast cells and platelets in peripheral blood and bone marrow with altered platelet aggregation has also been detected in AML-M7 (147). However, whether platelets or platelet stored mediators are directly involved in the evolution of AML-M7 has not previously been described. On the other hand, platelet stored mediators, which is also released by megakaryocytes, might be involved in myelofibrosis via PDGF and TGF-β (148) and in the transformation of AML-M7 into AML-M0 by PF-4 and β-TG (149). As previously described, these mediators are released into autografts during PBSCT (10) and might thereby be involved in the development of myelofibrosis after autotransplantation. As a result of observations that mediators which are stored and released by platelets seem to alter cell func-
tions in the bone marrow, we are lead to speculate that platelets can be involved in cellular alterations in bone marrows, including myelofibrosis and AML transformations.

Platelet effects on apoptosis
In addition to the effects of platelet released mediators on AML blasts as previously mentioned (3, 6, 7) it is worth noting that several studies hypothesize that platelets can have an affect on apoptosis of normal and malignant myelogenous cells as well (reviewed in [9]). ATP and Serotonin that are stored in platelet dense bodies, can affect apoptosis of the human HL-60 and K562 AML cell lines via receptor ligation (150–154). Furthermore, VEGF, PF-4 and PDGF interfere with the regulation of apoptosis in several cell types, including normal myeloid cells (48, 53, 155, 156), and may also interfere with apoptosis regulation in AML blasts that at least express receptors for PDGF and VEGF (6, 90).

The effects of platelets on cancer-associated angiogenesis
Platelets can release several proangiogenic mediators, including VEGF, PDGF, TGF-β and Ang-1 (see references in [157]). It is also known that TF can contribute to angiogenesis both through coagulation-dependent and independent mechanisms (17). Angiogenesis is also important for both leukemogenesis and chemosensitivity in AML, but at present it is not known whether or how platelets contribute to local angioregulation in the AML bone marrow.

The possible role of platelets during leukemogenesis
The studies reviewed above suggest that platelets can interact with primary AML cells and may contribute to AML cell proliferation, regulation of AML cell apoptosis and susceptibility to intensive chemotherapy. Thus, platelets may have a role in AML after the development of the disease and during treatment. However, the fundamental events in leukemogenesis are induction of genetic abnormalities that causes malignant transformation of these hematopoietic cells. Very few studies have addressed this question, but the current knowledge suggests that platelets may even contribute to the process of leukemogenesis.

Patients who have been recently diagnosed with AML can possibly be cured using conventional intensive chemotherapy, but more that half of those receiving this treatment will later on suffer a leukemia relapse. Relapsed AML shows chemoresistance and the only curative treatment is allogeneic stem cell transplantation. The development from newly diagnosed disease to chemoresistant relapse should be regarded as an additional step in leukemogenesis, and according to this new genetic abnormalities can be detected in relapse cells compared with the original cells. Many of the AML associated genetic abnormalities affect intracellular signalling pathways, including mutations in tyrosine kinase-associated receptor molecules (e.g. Flt3, c-kit) leading to constitutive tyrosine kinase activation (158). Many of these signalling pathways will converge on intracellular STAT molecules known to be important for regulation of proliferation, apoptosis and differentiation. Furthermore, the STAT molecules are also important mediators downstream to a wide range of hematopoietic growth factor receptors, and these growth factors are released in the AML cell microenvironment and affect both proliferation, survival and differentiation of the AML cells.

The next question is whether platelet-derived soluble mediators can interfere with growth-factor initiated, receptor-mediated intracellular signalling through the STAT molecules. We know that activated platelets can release several mediators (e.g. VEGF, PDGF, Ang-1) that can bind to receptors expressed on primary human AML cells and thereby alter the status of the STAT network through activation of receptor-associated tyrosine kinases (159, 160, 161). Thus, platelet-derived mediators can contribute to the overall tyrosine-associated signalling in AML cells, and thereby modulate the effects on the STAT system of exogenous hematopoietic growth factors and constitutively activated/mutated kinases receptors.

The final question remains whether platelet-induced modulation of the intracellular signalling from receptor tyrosine kinases (i.e. the STAT network) can lead to genetic instability and thereby contribute to the risk of inducing genetic abnormalities associated with leukemogenesis. This question has not been resolved, but a recent review described that constitutively activated/mutated tyrosine kinases can facilitate DNA repair through activation of cell cycle checkpoints and elevate the expression of intracellular antiapoptotic proteins (162). Despite these protective effects that facilitate malignant cell survival, the constitutive activity stimulates the generation of reactive oxygen species and enhance spontaneous DNA damage that will facilitate further leukemogenesis. At present it is only known that i) platelets release relevant soluble mediators; ii) AML cells express the corresponding receptors, and iii) the possibility exists that platelets can affect the intracellular signalling network and thereby modulate genetic instability and contribute to leukemogenesis and the development of chemoresistant AML relapse.

Another aspect of leukemogenesis is the development of AML from low-grade malignant diseases like chronic myeloid leukemia and myelodysplastic syndromes. The development of AML from these disorders is also associated with the detection of additional genetic abnormalities (162, 163), and platelets may then interfere with these steps in leukemogenesis through the same molecular mechanisms as previously described.

Conclusion
Platelets are capable of interacting with normal peripheral blood cells both via adhesion and soluble mediators. Similarly, platelet released mediators can affect hematopoietic stem and progenitor cells. These interactions may also be involved between platelets and circulating malignant cells, which is suggested by the effects platelets seem to have on metastasis and the various platelet defects that is detected in AML and other leukemias. However, the interactions between platelets and AML cells have only recently been characterized in detail. In-vitro studies clearly show that platelets and AML blasts can affect functional characteristics of each other. In addition, they also indicate that various chemotherapeutic drugs frequently used in AML therapy can alter platelet activation and other platelet functions. In-vivo studies reveal that the systemic levels of various cytokines are enhanced during AML chemotherapy, including cytokines that are known to affect both leukemic blasts and platelet activation. However, systemic platelet activation was not detectable during AML...
chemotherapy, but another platelet dysfunction was observed prior to chemotherapy for a subset of AML patients. These observations together with the other platelet dysfunctions detected in AML and the possible effects of chemotherapeutic drugs on platelet function cannot exclude the possibility of platelet secretion in AML and thereby the effect of platelets on circulating AML blasts. Platelet secretion of growth factors are clearly detected in PBSC autografts together with various hematopoietic growth factors. These observations may be of clinical importance because platelet released mediators may affect AML blast functions and might thereby influence the relapse risk after autotransplantation. Thus, platelets are most likely active participants during AML chemotherapy.

The big question remains whether the molecular mechanisms for interactions between platelets and AML cells are also relevant for other malignancies. Although many of the molecular substrates for interactions will also be present in other malignancies, this does not mean that they are operative and mediate clinically relevant effects. For several reasons one should be very careful to generalize to cancer in general from observations in AML:

There is heterogeneity even within the group of AML, and the biological differences will be even larger between AML and other malignancies.

AML cells show molecular and morphological signs of differentiation in various myeloid directions and would therefore be expected to behave differently from malignancies developing from other tissues. Both the cancer cells and the stromal elements will differ.

AML is a more aggressive disorder than may other malignancies, and the genetic abnormalities differ.

The leukemias show diffuse bone marrow infiltration, whereas most other malignancies show localized tumor growth and eventually distant metastasis to organs not usually involved in AML. The cancer cell microenvironment would therefore be expected to be very different.

Severe disease-induced thrombocytopenia is usually not found in solid tumors.

Thus, taken together, the overall data reviewed in this article suggest that platelets can directly or indirectly affect human AML cells and thereby influence disease development and response to therapy in these patients.

References


47. Foss, Bruserud: Platelets in AML, a review
93. Foss, Bruserud: Platelets in AML, a review
96. Foss, Bruserud: Platelets in AML, a review
102. Foss, Bruserud: Platelets in AML, a review